ARTICLE
29 January 2013

China Life Sciences Newsletter - January 2013

MF
Morrison & Foerster LLP

Contributor

Known for providing cutting-edge legal advice on matters that are redefining industries, Morrison & Foerster has 17 offices located in the United States, Asia, and Europe. Our clients include Fortune 100 companies, leading tech and life sciences companies, and some of the largest financial institutions. We also represent investment funds and startups.
The Fall/Winter 2012 issue of our China Life Sciences Newsletter, a periodic update on key developments, companies, and people in the dynamic China life sciences industry.
China Food, Drugs, Healthcare, Life Sciences

Welcome to the Fall/Winter 2012 issue of our China Life Sciences Newsletter, a periodic update on key developments, companies, and people in the dynamic China life sciences industry. In this issue, we bring you an interview with Dr. Dan Zhang, Founder and CEO of Fountain Medical Development, a full-service clinical CRO, based in South East Asia and China; the second of a three-part series discussing the strategic partnerships between Western and Chinese companies for the purpose of conducting early-stage pharma and biotech R&D (please find the first part in our Spring Issue); an analysis of compulsory patent licensing practices in China; and a discussion of new developments on the "patentable subject matter" requirement of U.S. patent law.

To read our newsletter, click here.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More